Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- One of many
- Global distribution of LF
- The parasitic life cycle
- Transmission is inefficient
- Epidemiology
- Disease caused by LF
- Most infection is silent
- Subclinical lymphatic damage
- Diagnosis of LF
- Blood collection timing
- Potential intervention targets
- Targeting the vector
- Targeting the parasite in humans
- The elimination strategy
- Combination therapy
- Elimination policy framework
- Committed donors for GPELF
- Mass drug administration
- How MDA is conducted
- Who is eligible for MDA?
- Are MDA drugs safe?
- MDA and existing morbidity
- Management and prevention
- Elements for success
- Monitoring and evaluation
- M&E: a strength of GPELF
- Key M&E elements
- LF mapping
- Coverage
- Assessing program impact
- Does MDA work?
- Determining when to stop MDA
- GPELF M&E framework
- Success of TAS
- TAS: indicating global progress
- GPELF progress: MDA status
- Challenges and opportunities
- Persistent infection
- Triple drug therapy
- Reaching IDA's potential
- TAS challenges
- Improving the TAS
- Surveillance challenges
- Don't forget those with disease
- Take home messages
- Acknowledgements
Topics Covered
- Lymphatic filariasis
- Wuchereria bancrofti
- Transmission of LF
- Diagnostic tools for LF
- Drugs to treat LF
- LF elimination strategy
- Conducting mass drug administration
- How do we measure progress and success?
- What are the challenges facing the program?
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Lammie, P. (2021, July 28). Elimination of lymphatic filariasis: adapting to reach the end game [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 2, 2024, from https://doi.org/10.69645/VYIF5852.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Patrick Lammie has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
HSTalks is pleased to grant unrestricted complimentary access to all lectures in the series Neglected Tropical Diseases. Persons not at a subscribing institution should sign up for a personal account.
Other Talks in the Series: Neglected Tropical Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Patrick Lammie,
and I'm the Director of the NTD Support Center at the Task Force for Global Health.
Today I'm going to talk about the elimination of lymphatic filariasis.
The global program to eliminate lymphatic filariasis (LF for short)
has been an enormous public health success over the past two decades,
reducing the number of infected people around the world by over 70 percent.
Nonetheless challenges remain, and some adaptations are needed for the
end game, the complete elimination of LF.
0:32
In my presentation today I'm going to: provide a quick overview of the biology of LF;
talk about the rationale and design of the LF elimination program;
discuss how we measure program impact;
and talk about the remaining challenges which must be solved, in order to achieve global success.
0:50
As a starting point, it's important to recognize that LF is one of a number
of neglected tropical diseases (NTDs) that are associated with poverty around the world.
NTDs affect more than a billion people.
They cause anemia, stunt childhood development, cause blindness, and chronic morbidity.
In terms of this presentation, it's important to recognize that a number of these diseases can be
controlled or eliminated using a common public health strategy,
that is mass drug administration (MDA).
For additional information on NTDs, I refer you to the presentation of Professor David Molyneux in this series,
1:30
LF is caused by three species of nematode parasites,
Wuchereria bancrofti, Brugia malayi, and Brugia timuri.
Of these, Wuchereria bancrofti is the most common, and is responsible for 90 percent of infections.
We describe LF as 'circumtropical', distributed in a broad belt around the equator.
As a historical note, W. bancrofti was first introduced to the Western Hemisphere by the slave trade,
and became established in most New World settings that had a plantation-based economy.